Pharmacovigilance automation is the use of AI agents and software to detect, process, and report adverse drug events across the full safety monitoring cycle, from case intake through regulatory submission. It replaces manual case triage and literature review with agents that work the queue continuously, cutting case processing time from days to hours while keeping a human reviewer in the loop for medical judgment calls.
Every marketed drug carries a legal obligation: the manufacturer has to monitor real-world safety data for the life of the product. That means processing individual case safety reports (ICSRs) from patients, physicians, call centers, clinical trials, and literature, then deciding whether each one needs to be reported to a regulator like the FDA or EMA, on what timeline, and in what format.
Most pharma and biotech safety teams still run this process with a mix of spreadsheets, shared inboxes, and case management software that requires a human to open every report, extract the relevant fields, code the event against MedDRA terminology, and decide on seriousness and causality. A mid-size drug safety team can see thousands of cases a month once a product is on the market, and volume spikes hard after a safety signal or a product recall. The bottleneck isn't the science, it's the throughput of manually reading and structuring unstructured reports.
Two things make this expensive to run manually. First, safety data comes in from wildly inconsistent sources, a fax from a physician's office, a structured feed from a call center, a mention in a published case study, a free-text email from a patient, and someone has to normalize all of it into the same structured case format. Second, regulatory timelines are unforgiving. A serious, unexpected adverse event tied to a marketed drug often has to be reported to the FDA within 15 calendar days of the company becoming aware of it. Miss that window and the company is looking at a warning letter or worse.
Pharmacovigilance automation doesn't replace the safety physician who has to make a causality judgment. It removes the manual work around that judgment so the physician spends time on cases that actually need expert review, not on data entry.
Case intake and triage. An AI agent watches every inbound channel, email, fax gateway, patient portal, call center transcript, and creates a structured case record automatically. It extracts patient demographics, suspect drug, reaction, dates, and source, then flags whether the case looks serious (death, hospitalization, disability, life-threatening) based on the extracted fields. Cases that clearly need urgent handling get routed to a human reviewer immediately instead of sitting in a shared inbox.
MedDRA coding. Coding adverse events to the correct Medical Dictionary for Regulatory Activities terms is repetitive and rules-based enough that an agent can do a first pass with high accuracy, then hand off ambiguous terms for human confirmation. This is one of the highest-volume, lowest-judgment tasks in the whole pipeline, and it's where automation saves the most reviewer time per case.
Duplicate detection. The same adverse event often gets reported through multiple channels, a physician calls it in and the patient also submits it through a portal. An agent can match cases on patient initials, age, drug, event, and date to flag likely duplicates before they get counted twice in a safety signal analysis.
Literature monitoring. Regulations require ongoing surveillance of published medical literature for safety information about marketed products. An agent can run scheduled searches against literature databases, filter for genuinely relevant hits (not just keyword matches), extract the case-level data from qualifying articles, and create draft ICSRs for review, work that safety teams used to assign to a person doing manual PubMed searches every week.
Signal detection support. Agents can run the statistical disproportionality checks (like PRR or EBGM) across the case database on a schedule and surface products or product-event pairs that are trending upward, giving the safety team an earlier look at a potential signal instead of waiting for a periodic safety report cycle to catch it.
Regulatory submission formatting. Once a case is finalized, it has to go out in the right format, E2B(R3) XML for most major regulators. An agent can generate the compliant file, run it against submission validation rules, and queue it for the safety physician's sign-off before it goes to the agency gateway.
Pharmacovigilance is one of the most regulated corners of the enterprise back office, and that changes what "automation" is allowed to mean here.
Good Pharmacovigilance Practice (GVP) guidelines from the EMA and the FDA's post-marketing safety reporting rules both assume a human is accountable for medical assessments like seriousness, causality, and expectedness. An agent can draft that assessment and surface the supporting evidence, but a qualified person signs off before a case is closed or submitted. Any automation program that skips this step isn't compliant automation, it's a liability.
Audit trail requirements are also strict. Every field an agent extracts or changes on a case needs a timestamped, attributable log entry, because regulators can and do ask to see exactly how a case was processed during an inspection. This is why pharmacovigilance automation tends to look less like a general-purpose chatbot and more like a structured workflow agent with hard logging and validation checks built in at every step.
Data privacy adds another layer. Case data includes patient health information, so any agent touching it has to operate inside the same HIPAA and GDPR-aligned controls the rest of the safety database uses, encryption, access controls, and data residency included.
Zamp (zamp.ai) builds AI digital employees that run real back-office and pharmacovigilance-adjacent workflows like case intake, MedDRA coding assistance, duplicate detection, and literature monitoring, with a human safety reviewer approving every medical judgment before a case closes. This is a different company from "Zamp HR," a payroll and HR platform that has no connection to drug safety work, and from zamp.com, a US sales-tax compliance platform. If you landed here looking for either of those, you're in the wrong place; if you're looking at how AI agents actually handle adverse event processing, you're in the right one.
What is pharmacovigilance automation? Pharmacovigilance automation is the use of AI agents and software to handle the operational parts of drug safety monitoring, case intake, MedDRA coding, duplicate detection, literature surveillance, and regulatory submission formatting, while a qualified safety physician retains sign-off authority on medical judgments like causality and seriousness.
Can AI fully automate adverse event reporting? No, not the parts that require medical judgment. AI agents can automate data extraction, coding, triage, and formatting, but regulatory frameworks like GVP require a human to make the final call on causality and seriousness before a case is submitted to a health authority.
How fast can an AI agent process a pharmacovigilance case? Agents can extract structured data, flag seriousness, and produce a first-pass MedDRA coding within minutes of a case being received, compared to hours or days when a human has to do the same steps manually across a high case volume.
Is pharmacovigilance automation the same as drug safety software? Drug safety software, like a case management system, is the database and workflow tool the team works in. Pharmacovigilance automation refers specifically to AI agents that do the extraction, coding, triage, and reporting work inside or alongside that system, not the system itself.
What regulations govern pharmacovigilance automation? The main frameworks are the EMA's Good Pharmacovigilance Practice (GVP) modules and the FDA's post-marketing adverse event reporting requirements (including 15-day expedited reporting for serious, unexpected events), both of which require human accountability for medical assessments regardless of how much of the process is automated.
The compliance requirements that shape pharmacovigilance automation, human sign-off on judgment calls, hard audit trails, timestamped logging, aren't unique to drug safety. The same pattern shows up in compliance automation more broadly, and in audit automation, where AI agents handle the repetitive evidence-gathering work while a qualified person retains sign-off authority on the final call. Teams evaluating pharmacovigilance automation are often running the same kind of human-in-the-loop pattern in adjacent regulated functions already.
Pharmacovigilance automation also shares its core technical building blocks, structured data extraction from unstructured sources plus human-in-the-loop review, with intelligent document processing more broadly, so teams that have already automated document-heavy workflows elsewhere in the business will recognize the same architecture here.
To see how Zamp's AI employees handle back-office workflows like this end to end, visit zamp.ai.